We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hutchmed (china) Limited | LSE:HCM | London | Ordinary Share | KYG4672N1198 | ORD USD0.10 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-7.00 | -2.59% | 263.00 | 263.00 | 275.00 | 263.00 | 263.00 | 263.00 | 3,956 | 09:08:15 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 838M | 100.78M | - | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
09/4/2024 08:55 | China Universal Asset Management Co. Ltd. lifted its position in HUTCHMED (China) Limited (NASDAQ:HCM – Free Report) by 353.7% in the fourth quarter, Holdings Channel reports. The firm owned 3,593 shares of the company’s stock after acquiring an additional 2,801 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in HUTCHMED were worth $65,000 as of its most recent filing with the Securities & Exchange Commission. Could be the reason? More in the link than that shared above, so more interest by more parties in the stock now? | lauders | |
09/4/2024 08:20 | Anyone know the rise today ? | its the oxman | |
02/4/2024 06:00 | More good news from HCM today: HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status | lauders | |
28/3/2024 08:01 | Yes…sNDA likely approval mid 25 and revenue in H2 25. Delivering as promised in their target pipeline development slide. | 1jat | |
28/3/2024 03:37 | Good news today but so far only 1% up in HK. HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC Further reading of the news states "......has been accepted for review by the China National Medical Products Administration (NMPA). If approved, the new label indication for savolitinib will be expanded to include treatment-naive patients in China. Hence the more muted response. Still, another step in the right direction. | lauders | |
14/3/2024 06:43 | Excellent share price performance and I admit I sold close to the bottom after years of frustration although did buy 3NVDL on Jan 2nd which is a 3x Nvidia Leveraged ETF so have done extremely well there. I will put some of my profits back into Hutchmed shortly. | nerdofsteel | |
12/3/2024 11:50 | There does appear to be a growing number of analysts expecting an earnings beat creating an expectation of rising share price | lomcovaks | |
12/3/2024 09:43 | I am not sure these moves on no news really mean anything…and could well be reversed tomorrow when the market takes fright at some statement coming from US/China that indicates more restrictions. The next news I will be looking for will be from Takeda… Their annual results are due in early/mid May and will contain the $15m sales from 2023 disclosed by HCM and the first three months of 2024. There may have been some stocking within the $15m and conversion of those on early access programs, but I hope they can sell $30m in Q1 and build to a $50m/quarter during 2024. This would give US in market sales of $150-180 and a $20m royalty (pure profit) to HCM (plus manufacturing fees). It was interesting to see in the company presentation that Europe is potentially a much larger market than the US. It did not appear that the EMA was giving priority status, so they may take longer than the US to approve…that will also be good news when it comes. | 1jat | |
12/3/2024 08:30 | Nice move today. Wish it would continue and some decent news would appear to maintain it! Can dream ;-) | lauders | |
28/2/2024 17:30 | fantastic results, great progress, one day they may attract a decent valuation; maybe that will be when they start generating free cashflow, but hopefully before that! | nerdofsteel | |
28/2/2024 12:23 | I have stuck with HCM through everything because in the end the story has not changed. Management has been ropey at times, but they are delivering the products and the cash is now coming in. Only politics holding them back and they are working their way round that. | dbadvn | |
28/2/2024 11:44 | Good results.Little to worry about other than the geopolitically afflicted rating! | steeplejack | |
28/2/2024 11:36 | Revenue grew 97%...Strengthened cash balance, with $886.3 million at year end (2022: $631.0m) | mcmather | |
27/2/2024 22:22 | Results tomorrow. | mcmather | |
22/2/2024 23:42 | Looking a bit better. Did we all get a response to emails sent to the co? | mcmather | |
08/2/2024 09:33 | AZ reporting $44m of orpathys sales. This would imply $30m revenue for HCM as flat on H1. | 1jat | |
06/2/2024 09:26 | I know what you mean NoS, having recently semi-retired…. As today’s 10% rise shows this can move quickly upwards…but as we know quickly down too…it is barely believable that all the gain associated with the Takeda deal and FDA approval has evaporated. | 1jat | |
03/2/2024 07:36 | thankyou 1jat, I do think that I will be buying at some stage, possibly later this year if or when the geo-politics issues subside. This is such a great under valued Company. My specific issue is one of oppoertunity cost here and my problem of effectively dead money and I have a specific timeframe to grow my investment and frankly time will run out! | nerdofsteel | |
03/2/2024 00:47 | More positive news yesterday and no positive impact on the share price. HCM really are in a rut at the moment. Thought 2024 was going to be better, but still 11 months to go. | lauders | |
02/2/2024 21:06 | NoS I for one will continue to value your thoughts…..as a long term follower of HCM I expect you will keep an eye on it, in case there is a change of tone and fortune - I also expect you will buy back in at some point… Good luck with your new investments….t | 1jat | |
02/2/2024 13:19 | Bareknee - Bitter posts just make it look like you're continually trying to validate your reasons for selling. Not at all, I was stating the facts as I see them.. | nerdofsteel | |
01/2/2024 17:38 | Let it go DaveyNerd. For better or worse you've sold up. Bitter posts just make it look like you're continually trying to validate your reasons for selling. It's like the reverse of the Quindell situation was for you. Live, learn and move on, but don't give up the day job ! | bareknee |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions